Last year, 2015, was a banner year for multiple myeloma treatment, with 5 new drugs approved by the US Food and Drug Administration. Two of those drugs, the monoclonal antibody elotuzumab and the proteasome inhibitor, ixazomib, were approved in November, following promising phase 3 clinical trial results, in combination with standard multiple myeloma therapies, the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone, in the second-line setting. Notably, the approval of ixazomib marks the availability of the first all-oral regimen for multiple myeloma.
Click on the PDF icon at the top of this introduction to read the full article.